GBM PAXALISIB ESMO 09/09/2022, page-3

Well, Well, Well.
The recently completed phase 2 trial (NCT03522298) enrolled patients with newly diagnosed GBM with unmethylated MGMT promoter status following surgical resection and chemotherapy
Dr Wen and Dr De Groot were encouraged with Kazia's paxalisib phase 2 final trial results, enough to present an abstract and discuss the results at the upcoming ESMO Congress 2022, They also they joined the Kazia Scientific Advisory Board (SAB).
Dr Wen and Dr De Groot should have enough influence and clout to guide the GBM AGILE investigators who are continuously analyzing the data from the paxalisib study arm, especially for the data results relating to the enrolled patients with newly diagnosed GBM with unmethylated MGMT promoter status.

Regards.